14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $23.53 $28.69 Thursday, 25th Apr 2024 INSM stock ended at $24.92. This is 3.45% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 2.50% from a day low at $24.82 to a day high of $25.44.
90 days $23.53 $29.91
52 weeks $18.09 $32.00

Historical Insmed prices

Date Open High Low Close Volume
Apr 25, 2024 $25.44 $25.44 $24.82 $24.92 1 164 159
Apr 24, 2024 $25.58 $25.96 $25.38 $25.81 2 518 248
Apr 23, 2024 $25.03 $25.81 $24.56 $25.27 2 022 522
Apr 22, 2024 $24.37 $25.15 $23.55 $24.11 2 644 532
Apr 19, 2024 $24.86 $25.87 $23.53 $24.32 5 534 124
Apr 18, 2024 $26.07 $26.31 $24.77 $24.80 2 214 879
Apr 17, 2024 $26.24 $26.54 $25.85 $26.18 1 127 699
Apr 16, 2024 $26.87 $26.97 $26.11 $26.15 1 960 059
Apr 15, 2024 $27.09 $27.22 $26.40 $26.82 1 757 063
Apr 12, 2024 $28.39 $28.46 $26.95 $27.25 2 617 154
Apr 11, 2024 $28.69 $28.69 $28.01 $28.56 944 228
Apr 10, 2024 $27.59 $28.43 $27.26 $28.39 1 112 441
Apr 09, 2024 $28.20 $28.33 $27.74 $28.01 1 194 354
Apr 08, 2024 $27.65 $28.14 $27.56 $28.11 983 122
Apr 05, 2024 $27.20 $28.07 $26.92 $27.66 1 587 715
Apr 04, 2024 $27.68 $27.91 $27.14 $27.28 2 465 280
Apr 03, 2024 $26.07 $27.75 $25.99 $27.68 2 004 937
Apr 02, 2024 $26.65 $26.65 $25.83 $26.30 3 019 783
Apr 01, 2024 $26.90 $27.10 $26.44 $26.72 2 212 551
Mar 28, 2024 $27.22 $27.55 $27.01 $27.13 1 071 582
Mar 27, 2024 $27.02 $27.41 $26.71 $27.32 1 181 424
Mar 26, 2024 $27.29 $27.41 $26.95 $27.02 1 138 077
Mar 25, 2024 $26.50 $27.01 $26.19 $27.00 799 160
Mar 22, 2024 $26.57 $26.61 $26.02 $26.43 942 599
Mar 21, 2024 $26.83 $27.08 $26.34 $26.34 892 030
Click to get the best stock tips daily for free!

About Insmed

Insmed Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr... INSM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT